With a new start­up, ARCH and Take­da wade in­to grow­ing search for a Swiss Army knife RNA drug

ARCH and Take­da are step­ping — if not quite leap­ing — in­to one of the hottest new ar­eas in RNA drug de­vel­op­ment: tR­NA.

On Wednes­day the promi­nent VC firm and the Japan­ese phar­ma, along with tech-ori­ent­ed 8VC, an­nounced a $24 mil­lion in­vest­ment in hC Bio­science, a new start­up that will try to use this once-over­looked cor­ner of ge­net­ic ma­chin­ery to de­vel­op treat­ments for rare dis­eases and can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER